BUZZ-Ideaya rises as FDA clears trial for experimental cancer drug

Reuters12-01
BUZZ-Ideaya rises as FDA clears trial for experimental cancer drug

** Shares of California-based drug developer Ideaya Biosciences IDYA.O rise 3.3% to $36.80 premarket

** Co says it has received clearance from U.S. FDA to begin its first human trial on its new experimental cancer drug, IDE034, which is designed to target several common types of solid tumors

** Drug targets B7H3 and PTK7 proteins, often found together in lung, colorectal and head & neck cancers - IDYA

** Co says these proteins are present in up to 46% of colorectal cancers, 30% of lung cancers, and 27% of head and neck cancers

** In animal studies, IDE034 showed strong tumor-fighting effects, both on its own and when combined with co's another drug, IDE161 - IDYA

** Co to begin enrolling patients in Q1 2026; more data expected at H1 2026 medical meeting

** Up to last close, stock up ~39% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment